Compounds > lotrafiban
Page last updated: 2024-08-25

lotrafiban and Bleeding

lotrafiban has been researched along with Bleeding in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Amarenco, P; Califf, RM; Davis, S; Diener, HC; Easton, D; Ferguson, J; Fitzgerald, D; Graffagnino, C; Granett, J; Harrington, RA; Koudstaal, PJ; Pieper, K; Shuaib, A; Sigmon, K; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F; Willerson, JT1
Armstrong, PW; Califf, RM; Card, T; Chan, R; Graffagnino, C; Granett, J; Harrington, RA; Joseph, DM; Kereiakes, DJ; Samuels, R; Sigmon, KN; Topol, EJ; Van De Werf, F1
SoRelle, R1
Aluri, J; Chapelsky, M; Granett, J; Mould, D; Samuels, R; Swagzdis, J1

Trials

3 trial(s) available for lotrafiban and Bleeding

ArticleYear
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
    Circulation, 2003, Jul-29, Volume: 108, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Benzodiazepines; Cerebrovascular Disorders; Coronary Disease; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Multivariate Analysis; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Risk Assessment; Treatment Outcome

2003
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease.
    Circulation, 2000, Aug-15, Volume: 102, Issue:7

    Topics: Administration, Oral; Aged; Benzodiazepines; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Intracranial Arteriosclerosis; Male; Middle Aged; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombocytopenia; Treatment Outcome

2000
A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
    Clinical pharmacology and therapeutics, 2001, Volume: 69, Issue:4

    Topics: Adult; Age Factors; Aged; Benzodiazepines; Creatinine; Demography; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Diseases; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors

2001

Other Studies

1 other study(ies) available for lotrafiban and Bleeding

ArticleYear
SmithKline Beecham halts tests of lotrafiban, an oral glycoprotein IIb/IIIa inhibitor.
    Circulation, 2001, Jan-02, Volume: 103, Issue:1

    Topics: Administration, Oral; Benzodiazepines; Clinical Trials, Phase III as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stroke; Treatment Outcome

2001